Three standout stocks are ready to deliver seasonal gains.Unlock Cyber Monday savings! Get 60% off InvestingPro and access top features like ProPicks AI, Fair Value, and the Top Stock Screener for just $6/month.
The second is the strong upside potential, with analysts predicting substantial growth in the medium term. Let’s unwrap these opportunities.Its areas include immunology, oncology, neurosciences, and aesthetics. ABBV's market capitalization stands at an impressive $323.2 billion. In the most recent quarter, it again beat forecasts, marking its 14th earnings improvement in the last 16 quarters. It also closed the quarter with a cash balance of $7.3 billion, lower than its short-term debt levels of $12.6 billion.AbbVie's flagship product Humira, once the world's best-selling drug, has faced revenue pressures since the expiration of its exclusivity rights in February 2024.
In 1968, the company abbreviated its name by taking the first three letters of each word to create a more easily recognizable brand name. We will learn about its quarterly financials on February 18. Earnings per share are expected to rise by 55.1% in 2024 and 13.4% in 2025. Its dividend yield is 4.28% and has maintained a strong consistent payout schedule for 20 consecutive quarters. Its payout since 2019 has risen quite strongly.It will release its quarterly report on February 19, with earnings per share expected to increase by 9.13%. The company remains optimistic about its growth prospects, including expansion plans in Mexico.It features 8 ratings, of which 6 are buy, 2 are hold and none are sell.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Herkunft: Investingcom - 🏆 450. / 53 Weiterlesen »
Herkunft: Investingcom - 🏆 450. / 53 Weiterlesen »
Herkunft: Investingcom - 🏆 450. / 53 Weiterlesen »
Herkunft: Investingcom - 🏆 450. / 53 Weiterlesen »